Phase I clinical trial of CO17-1A monoclonal antibody.
Twenty patients with metastatic gastrointestinal cancer received one or more weekly infusions of 400 mg CO17-1A monoclonal antibody. The most common side effect was mild gastrointestinal symptoms in 9/20 patients. Two of five patients receiving three weekly infusions had reversible anaphylactic reactions at the time of their third infusion. The pharmacokinetics of the antibody were similar at the first, second or third infusion. Human antibody to 17-1A occurred in 17/20 patients with 11/20 having antibody detectable by 8 days following initial infusion. Thus, one or two infusions (weekly) of large doses of 17-1A were well tolerated but allergic responses limit ability to administer therapy by 15 days post-initial infusion.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use / Q000633:toxicity*; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy*; D004341:Drug Evaluation; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D013274:Stomach Neoplasms / Q000276:immunology / Q000628:therapy*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal